Articles tagged with Tumor Necrosis Factors
This study investigates TNIP1's role in regulating cell proliferation and apoptosis in breast cancer. TNIP1 knockdown was found to induce growth arrest and activate the NF-κB pathway, leading to increased apoptosis in breast cancer cells. The findings highlight TNIP1 as a crucial marker for breast cancer therapies.
Researchers used AI to find adalimumab as potential treatment for iMCD, a rare disease with poor survival rate and few treatment options. The treatment has shown promising results in saving the life of a patient who was on hospice care.
Early treatment with TNF inhibitors has been shown to prevent complications in kids with Crohn's disease, reducing the risk of perianal fistulas by 82%. The study found that anti-TNF drugs are specifically effective in preventing these debilitating complications, making them a recommended first-line therapy.
Researchers at Texas Biomedical Research Institute developed a human cell culture model of alveolar macrophages, which helped make a key finding about the role of tumor necrosis factor (TNF) in tuberculosis (TB). The study found that TNF is critical to protect against TB but not other infectious diseases.
Researchers found that the frequency of activated TREG cells remained elevated during treatment and continued to be high even after the virus was eliminated. Inflammatory features, such as increased TNF signaling, were sustained in TREG cells, indicating long-term immune system changes induced by the chronic infection.
A study found a significant association between the TNFSF15 rs4979462 gene variant and increased risk of systemic lupus erythematosus (SLE) in female patients. Higher TNFSF15 serum levels were also correlated with SLE disease activity, suggesting this protein could be a biological marker for the disease.
Researchers develop technology that alleviates retinal pathologies by targeting mitochondrial chaperone TRAP1, which is implicated in the breakdown of blood-retinal barrier and pathological neovascularization. This treatment approach holds great promise for revolutionizing the treatment landscape for ischemic retinopathy.
A new study has found that tumor necrosis factor inhibitors, commonly used for inflammatory arthritis, are not associated with poor pregnancy outcomes. Women who continued treatment had lower risks of severe infections postpartum compared to those who stopped. The results provide reassuring data on the use of TNF blockers during pregna...
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.
Researchers from the University of North Carolina Health Care announce that patients receiving anti-TNF biologic treatments combined with methotrexate had better outcomes than those treated with adalimumab alone. The study, published in Gastroenterology, provides clear results that can immediately impact patient care.
Researchers at La Jolla Institute for Immunology have found that the inflammatory molecule LIGHT leads to airway remodeling and long-term breathing issues in severe asthma. Therapeutics targeting LIGHT could reverse airway and lung damage, offering a potential long-term treatment for asthma.
A study at Washington State University has identified sulfatase-2 as a critical protein driving damage caused by rheumatoid arthritis. The discovery sheds light on molecular processes behind inflammation in the disease and could lead to improved treatments.
A new study demonstrates that glyphosate successfully crosses the blood-brain barrier and enhances TNF-α levels in mice. The herbicide is linked to increased production of soluble beta amyloid and reduced neuron viability, suggesting potential hazards to neurological health.
Dixit's work on programmed cell death and inflammation has led to therapies for autoimmune disorders and rheumatoid arthritis. The Vilcek Foundation recognizes his contributions as an immigrant scientist in the US.
Researchers at UC Riverside have discovered that targeting the TNFR1 receptor may be a more effective approach to treating inflammatory bowel disease. By selectively blocking TNFR1, they found significant benefits in mice with Crohn's-like ileitis, suggesting this approach could offer a new opportunity for healing.
Researchers at UC Davis Health developed a new treatment that simultaneously blocks IL-6 and TNF cytokines, providing superior protection against acute graft-versus-host-disease severity and mortality. The dual-cytokine blockade approach did not impair beneficial graft-versus-tumor effects.
A rare rheumatoid-like autoinflammatory condition is found to be treatable with FDA-approved TNF inhibitors due to the absence of a protein that activates antiviral defenses. Researchers confirm its underlying biology and mechanisms of autoinflammation, leading to quick and substantial clinical improvement.
Scientists at the University of Southampton have found that TNF receptor activation requires receptor clustering, but smaller clusters with higher density activate receptors better than larger ones. This discovery could guide future development of therapeutic antibodies targeting TNF receptors.
A recent EULAR study found that treatment with tumor necrosis factor inhibitors can slow the progression of radiographic sacroiliitis in patients with axSpA. This effect becomes apparent 2-4 years after treatment initiation, according to the research.
A team of scientists discovered that mast cells orchestrate the recruitment of neutrophils through a molecular mechanism involving tumor necrosis factor. Mast cells position themselves around blood vessels and release TNF, which activates surface proteins on neutrophils, allowing them to migrate into tissues.
Stomach cancers may respond to medicines that inhibit TNF, a protein involved in inflammation and disease progression. The discovery was made using a laboratory model of stomach cancer and suggests a potential new therapeutic target for this devastating disease.
A new study by Children's Hospital Los Angeles reveals that tumor necrosis factor (TNF) plays a complex role in inflammatory bowel disease (IBD), with implications for future therapies. Researchers found that TNF signaling and receptor activation developmentally may be more important than simply blocking the molecule.
Higher HMGB1 levels associated with obesity, inflammation and cardiovascular disease in younger adults, particularly females and blacks. The study found a link between circulating HMGB1 levels and increased blood pressure, stiffer arteries and inflammation.
Researchers have identified chronic inflammation as the primary driver of accelerated aging, leading to a range of diseases including Alzheimer's, atherosclerosis and cancer. This discovery opens up new avenues for early diagnosis, prevention and treatment of these conditions.
A new study found that the live zoster vaccine is safe and effective in patients taking TNF inhibitors, with no cases of confirmed disseminated or local varicella infection. The researchers observed a very low risk of infection, with an upper bound confidence interval of approximately one percent.
A population-based cohort study from 4 Nordic countries found no link between TNFi use and increased cancer risk. However, a significant increase in malignant lymphomas was observed within the trial. Further analysis is needed to determine if this is due to psoriatic arthritis or TNFi treatment.
Researchers at the University of Navarra found that pretreating patients with TNF inhibitors before combining immunotherapy can reduce adverse effects and improve treatment response in animal models. The study suggests a new approach to treating cancer by blocking tumor necrosis factor while applying combination immunotherapy.
A synthetic peptide has been found to directly disrupt destructive inflammation in the kidneys, enabling better recovery and maintaining important functions. The peptide reduced immune cell movement, resolved inflammation, and improved kidney function without increasing blood pressure.
Researchers have found a compound that reduces IBD symptoms in mice by blocking the activity of a gene linked to blood clotting. This compound may be a new therapeutic option for people with severe IBD or those who don't respond to current treatments.
A new assay accurately measures TNF concentrations during adalimumab treatment, revealing that circulating TNF levels increase 50-fold before stabilizing. Lower TNF concentrations after the fourth week are associated with more antibodies against the drug and a lower chance of remission.
Researchers found a new protein iTAP that regulates TNF release from immune cells, reducing its levels in circulation. This discovery offers potential for developing improved treatments for inflammatory diseases.
A cohort study showed that adding non-steroidal anti-inflammatory drugs (NSAIDs) to tumour necrosis factor (TNF) inhibitors can slow radiographic progression in patients with ankylosing spondylitis. Celecoxib, a specific NSAID, was associated with the greatest reduction in radiographic progression.
A study found that pregnant women with rheumatoid arthritis using certain RA drugs did not have a marked excess risk of serious side effects compared to unexposed children. The research showed that TNF inhibitors may not compromise the child's ability to fight infections.
Researchers aim to understand how TNF works to reduce inflammation and develop more precise treatment options for patients with inflammatory bowel disease (IBD). The study builds on previous research demonstrating TNF's dual role in promoting and reducing inflammation.
A recent study published in Cell Reports found that the protein iRhom2 regulates the release of important molecules triggering the inflammatory response. This mechanism is also crucial for controlling growth factors associated with certain cancers.
Researchers at NYU School of Medicine discovered that infliximab blocks TNF-alpha, reducing inflammation in the gut and preventing transplant rejection. They also found that stimulating ATG16L1 protects against TNF-alpha driven inflammation.
A study found that age and obesity create a perfect storm that damages the tiny blood vessels that directly feed the heart muscle, leading to reduced blood flow and increased risk of heart failure. The inflammation caused by both factors thickens the walls of these microvasculature, making them less able to dilate and sustain the heart.
F8-TNF stimulates killer cells to target sarcomas by identifying them through dormant viral proteins, offering a new avenue for cancer immunotherapy. The treatment has been shown to completely cure mice of sarcoma and grant immune protection against tumor recurrence.
Researchers developed a new virtual drug screening platform to predict interactions with TNF and RANKL proteins. Two promising molecules, T23 and T8, were identified as strong TNF inhibitors with low potential for side effects.
Researchers at McMaster University found that imbalances in gut microbes lead to intestinal leakage, triggering inflammation, impaired immune function, and reduced lifespan. The study suggests targeting age-associated inflammation may improve immune health and reduce the risk of chronic conditions.
Researchers discovered that tumor necrosis factor (TNF) regulates small blood vessel function and blood pressure by acting as a mechanosensor. TNF controls blood pressure, and drugs that interfere with TNF signaling can dramatically reduce it.
A new biosimilar called CT-P13 has been found safe and effective in treating Crohn's disease and ulcerative colitis, with a clinical response achieved in over 70% of patients at short-term follow-up. The treatment offers a cost-effective alternative to infliximab, a costly biologic therapy.
University of Groningen scientists discovered that tumor necrosis factor receptor 2 (TNFR2) is essential for preventing neuronal death in neurodegenerative diseases like multiple sclerosis and Alzheimer's. A specific TNFR2 agonist may prevent cell death, offering a new treatment direction.
Researchers identified otulipenia as a rare inflammatory disease affecting young children, characterized by fever, skin rashes, diarrhea, and joint pain. The condition is caused by the malfunction of OTULIN, a single gene on chromosome 5, leading to an overproduction of inflammatory cytokines.
Adalimumab, an inhibitor of the inflammatory protein tumor necrosis factor (TNF), has been shown to provide significantly greater symptom relief than placebo in patients with hidradenitis suppurtiva. The results of two phase 3 clinical trials support FDA approval of adalimumab for this painful skin condition.
Researchers discovered TNF's mechanism to protect against intracellular pathogens like Leishmania major. By inhibiting arginase 1, TNF increases nitric oxide production, which suppresses the pathogens, providing a plausible explanation for increased infection susceptibility during anti-TNF treatments.
Researchers found that an extra-low dose combination of two anticytokines reduced rheumatoid arthritis disease activity and cardiovascular events. The study showed a lower incidence of cardiovascular events in patients treated with the combination, suggesting decreased cardiovascular risk.
HUMIRA enhances the function of TNF in rheumatoid arthritis patients by increasing its expression on monocytes and promoting membrane-bound TNF-RII binding. This leads to the activation of anti-inflammatory T cells that can suppress inflammation.
Researchers at the University of Bonn have identified an immune factor responsible for chronic viral infections. The study found that a molecule called tumor necrosis factor (TNF) impairs the immune response in these cases.
Scientists designed a novel bispecific antibody that selectively blocks overproduction of TNF, a protein harmful when overproduced in autoimmune diseases. The prototype shows promise for treating conditions such as rheumatoid arthritis and Crohn's disease.
A study has identified a potential link between inflammation caused by rheumatoid arthritis and the development of heart valve disease, including aneurysms. The research team hopes that existing medicines that dampen inflammation could be repurposed to treat heart valve diseases.
Scientists have isolated the smallest unit of sleep, discovering that it originates from small neural networks. The research, published in European Journal of Neuroscience, allows for the independent isolation of sleep for research without physiological factors.
A recent UK study found that 40% of rheumatoid arthritis patients scored low on an adherence questionnaire, indicating inconsistent medication use. The research highlights the need for healthcare professionals to better inform patients about the importance of taking drugs as prescribed.
Research from Monell Center reveals that tumor necrosis factor (TNF) helps regulate sensitivity to bitter taste. In normal mice, TNF makes foods taste more bitter during illness due to increased sensitivity. This finding may explain the decreased food intake associated with infections and chronic inflammatory diseases.
Duke researchers have identified the uhrf1 gene as a key regulator of tumor necrosis factor (TNF) levels, which are associated with inflammatory bowel diseases like Crohn's disease and ulcerative colitis. The study found that loss of uhrf1 leads to increased TNF production, which can cause inflammation and damage to the digestive tract.
Researchers found high TNF alpha levels in tumor tissue correlate with increased numbers of activated killer cells and a favorable course of the disease. The study suggests that TNF alpha could serve as an independent biomarker for disease prognosis.
Mayo Clinic researchers have found a potential link between TNF inhibitors and increased risk of uveal melanoma in patients. Patients taking TNF inhibitors should undergo regular eye exams to monitor for any issues.
Researchers discovered that GILZ protein can reduce bone loss and inflammation associated with arthritis, potentially replacing synthetic glucocorticoids as a treatment option. The study used mice bred with overexpressed tumor necrosis factor alpha and GILZ to demonstrate the protein's protective effects.
A new study reveals that humans and corals have a shared biomechanical pathway responsible for triggering cellular self-destruction. This finding has important implications for understanding the early evolution of multicellular life, conservation of corals, and development of new drugs to fight diseases like cancer.
Researchers found that excess tumor necrosis factor production initially kills TB pathogens, but later encourages their growth. Certain drug combinations can reverse this effect, potentially reverting hypersusceptibility to hyperresistance.